Worth reading
57In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
713
¥ million (year-on-year increase in revenue)Wording
Conditional
How definitive the wording is.Contents of this document
Supplementary materials to the earnings reportThird quarter of the fiscal year ending June 20269 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥18,334 million+4.0%
Operating profit¥4,580 million+4.5%
Ordinary income¥4,551 million+3.0%
Net income¥3,052 million+3.1%
Operating profit margin25 %
Full-year earnings forecast
Consolidated revenue
¥25,700 million
Consolidated operating profit
¥5,430 million
Consolidated ordinary income
¥5,430 million
Profit attributable to owners of the parent
¥3,640 million
Depreciation and amortization
¥673 million
Research and development costs
¥217 million
Capital expenditures
¥2,699 million
Progress against full-year forecast 通期の予想に対して、いまどこまで進んだかの割合です。
Consolidated revenue71.3
Consolidated operating profit84.3
What the company explained in this material
Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
- Revenue increase¥713 million
- Increase in costs of sales¥-371 million
- Increase in selling, general and administrative expenses¥-143 million
- Non-operating income and expenses (foreign exchange losses and other items)¥-66 million
- Total change in ordinary income¥132 million
Key KPIsA metric the company considers important as a management benchmark.
- Active Pharmaceutical Ingredients segment margin21.1 %
- Pharmaceuticals segment margin27.5 %Year on year against the same period last year-0.6%
- Share of sales from products launched since 202521.1 %Year on year against the same period last year+0.7%
Segment results
Active Pharmaceutical Ingredients Segment
Net Sales
¥12,248 million+4.4%
Operating profit
¥2,588 million+8.3%
Active Pharmaceutical Ingredients Segment (External Sales)
Net Sales
¥11,309 million+5.3%
Internal sales
¥939 million-5.5%
Pharmaceuticals Segment
Net Sales
¥7,024 million+2.1%
Operating profit
¥1,931 million-0.1%
Adjustments
Net Sales
¥-939 million-5.5%
Operating profit
¥61 million+1.2%
Medium-term management plan targets
Fiscal year ending June 2028
Consolidated revenue
¥31,900 million
Consolidated operating profit
¥6,530 million
Fiscal year ending June 2030
Consolidated operating profit
¥8,000 million
Financial targets
ROE
TargetAt least 12%
Actual results
Fiscal year ended June 202412.8
Fiscal year ended June 202513.7
Number of employees
Number of Employees304 people
As of30 June 2025
Capital expenditures
¥1,735 million
Annual Dividend
Annual dividend per share
¥18
Payout ratio
Target of 20% or higher
| Item | Details |
|---|---|
| Document type | Supplementary materials to the earnings report |
| Fiscal Period Covered | Third quarter of the fiscal year ending June 2026 |
| Net Sales | ¥18,334 million (YoY +4.0%) |
| Operating profit | ¥4,580 million (YoY +4.5%) |
| Ordinary income | ¥4,551 million (YoY +3.0%) |
| Net income | ¥3,052 million (YoY +3.1%) |
| Operating profit margin | 25 % |
| Full-year earnings forecast | Consolidated revenue ¥25,700 million / Consolidated operating profit ¥5,430 million / Consolidated ordinary income ¥5,430 million / Profit attributable to owners of the parent ¥3,640 million / Depreciation and amortization ¥673 million / Research and development costs ¥217 million / Capital expenditures ¥2,699 million |
| Progress against full-year forecast | Consolidated revenue 71.3 / Consolidated operating profit 84.3 |
| Segment results | Active Pharmaceutical Ingredients Segment Net Sales ¥12,248 million (YoY +4.4%) / Operating profit ¥2,588 million (YoY +8.3%) / Active Pharmaceutical Ingredients Segment (External Sales) Net Sales ¥11,309 million (YoY +5.3%) / Internal sales ¥939 million (YoY -5.5%) / Pharmaceuticals Segment Net Sales ¥7,024 million (YoY +2.1%) / Operating profit ¥1,931 million (YoY -0.1%) / Adjustments Net Sales ¥-939 million (YoY -5.5%) / Operating profit ¥61 million (YoY +1.2%) |
| Breakdown of Factors Affecting the Change | Factors Revenue increase / Amount ¥713 million, Factors Increase in costs of sales / Amount ¥-371 million, Factors Increase in selling, general and administrative expenses / Amount ¥-143 million, Factors Non-operating income and expenses (foreign exchange losses and other items) / Amount ¥-66 million, Factors Total change in ordinary income / Amount ¥132 million |
| Key KPIs | Indicator name Active Pharmaceutical Ingredients segment margin / Value 21.1 % / Year on year against the same period last year Not disclosed, Indicator name Pharmaceuticals segment margin / Value 27.5 % / Year on year against the same period last year -0.6 %, Indicator name Share of sales from products launched since 2025 / Value 21.1 % / Year on year against the same period last year 0.7 % |
| Number of employees | Number of Employees 304 people / As of 30 June 2025 |
| Medium-term management plan targets | Fiscal year ending June 2028 Consolidated revenue ¥31,900 million / Consolidated operating profit ¥6,530 million / Fiscal year ending June 2030 Consolidated operating profit ¥8,000 million |
| Financial targets | ROE Target At least 12% / Actual results Fiscal year ended June 2024 12.8 / Fiscal year ended June 2025 13.7 |
| Annual Dividend | Annual dividend per share ¥18 / Interim Not disclosed / End of period Not disclosed |
| Payout ratio | Target of 20% or higher |
| Capital expenditures | ¥1,735 million |
Items this document does not state (13)
Gross Profit MarginSelling, general and administrative expensesResults for the three months of the current quarterSelf-assessment against the planUnit price and quantity metricsNumber of stores and locationsAssumptions Underlying the Business OutlookRisk amount incorporated into the outlookAcquisition of treasury sharesOrders received and order backlogMarket Size / ShareKey points of the Q&ANew initiatives
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.In the Active Pharmaceutical Ingredients segment, transaction volumes increased as products launched in recent years gained market penetration and generic drugs expanded their volume share. In the Pharmaceuticals segment, prefilled syringe products and anticancer vial products manufactured at the Zao Plant performed solidly, while sales of the core tablet products manufactured at the Head Office Plant declined due to new competitor entries and other factors.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.